X

Trial Profile

A Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System Metastases (CNS) From BRAF V600-Mutated Metastatic Melanoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs E 6201 (Primary) ; Dabrafenib
Indications Brain metastases; Malignant melanoma
Focus Therapeutic Use
Sponsors Spirita Oncology; Strategia Therapeutics

Most Recent Events

10 Apr 2024 Trial design presented at the 115th Annual Meeting of the American Association for Cancer Research
05 Mar 2022 Status changed from recruiting to discontinued.
13 Nov 2018 The trial design has been changed from sequential to single group assignment. Also, Endpoints and treatment arms has been amended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com